source
- Study finds Lilly's obesity drug Zepbound may lower hospital and ER costs for older adultsA real‑world analysis examined older patients with obesity or excess weight who were either treated with Eli Lilly’s drug Zepbound or not. The researchers tracked healthcare utilization over time t…
- FDA greenlights Revolution Medicines' pancreatic cancer gamechangerFollowing dynamite data that earned a standing ovation at the American Society of Clinical Oncology meeting in May, Revolution Medicines’ Ras inhibitor daraxonrasib has been approved by the FDA for…Fierce Biotech · 6h ago↗ source